These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 7553302)
1. Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses? Lamm DL; van der Meijden AP; Akaza H; Brendler C; Hedlund PO; Mizutani Y; Ratliff TL; Robinson MR; Shinka T Int J Urol; 1995 Jun; 2 Suppl 2():23-35. PubMed ID: 7553302 [No Abstract] [Full Text] [Related]
3. Risk-adapted use of intravesical immunotherapy. Braasch MR; Böhle A; O'Donnell MA BJU Int; 2008 Nov; 102(9 Pt B):1254-64. PubMed ID: 19035890 [No Abstract] [Full Text] [Related]
4. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Huncharek M; Kupelnick B Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895 [TBL] [Abstract][Full Text] [Related]
5. Risk-adapted use of intravesical chemotherapy. Lerner SP; Au JL BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889 [No Abstract] [Full Text] [Related]
6. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder. Pham HT; Soloway MS Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909 [TBL] [Abstract][Full Text] [Related]
7. [BCG therapy. Its role in the treatment of tumors of the bladder]. Patard JJ; Chopin DK; Abbou CC Ann Urol (Paris); 1995; 29(5):292-3. PubMed ID: 8638911 [No Abstract] [Full Text] [Related]
8. Management of superficial transitional cell carcinoma of the bladder. Fleischmann J; Goldberg G Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825 [TBL] [Abstract][Full Text] [Related]
10. [Treatment and follow-up of superficial bladder cancer]. Raitanen M Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168 [No Abstract] [Full Text] [Related]
11. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer. Huben RP Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806 [TBL] [Abstract][Full Text] [Related]
12. BCG in bladder cancer. Meek D Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457 [TBL] [Abstract][Full Text] [Related]
13. Diagnosis and treatment of superficial bladder cancer: an update. Crawford ED Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804 [TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer? Lamm DL Cancer Surv; 1998; 31():99-108. PubMed ID: 15281319 [TBL] [Abstract][Full Text] [Related]
15. Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment? Sylvester RJ Eur Urol; 2007 Oct; 52(4):951-3; discussion 953-4. PubMed ID: 17374437 [No Abstract] [Full Text] [Related]
17. Serial urinary IL-2, IL-6, IL-8, TNFalpha, UBC, CYFRA 21-1 and NMP22 during follow-up of patients with bladder cancer receiving intravesical BCG. Sanchez-Carbayo M; Urrutia M; Romani R; Herrero M; Gonzalez de Buitrago JM; Navajo JA Anticancer Res; 2001; 21(4B):3041-7. PubMed ID: 11712808 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Lamm DL Clin Infect Dis; 2000 Sep; 31 Suppl 3():S86-90. PubMed ID: 11010830 [TBL] [Abstract][Full Text] [Related]
19. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review]. Patard JJ; Chopin DK Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876 [TBL] [Abstract][Full Text] [Related]